Placeholder

LabCentral Houses Scientific Visionaries
Engaged in Early-Stage Research

TRV52

TRV52 is a preclinical-stage therapeutics company focused on modulating the autophagy pathway to address unmet medical needs and transform the lives of patients. 

TRV52 logo
Website - Coming Soon
  • Keith Dionne, PhD CEO
  • Jonathan Goodwin, PhD Senior Scientist, Biology